Targeting ID2 to augment doxorubicin antitumor efficacy and enhance antibacterial defense without neutropenia
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.117328 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Xinyu Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological and Chemical Engineering, Changsha University, Changsha 410022, Hunan, China. Hauptthemen laut MEDLINE: Inhibitor of Differentiation Protein 2, Doxorubicin, Neutropenia, Neutrophils. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation, Education Department of Hunan Province, Scientific Research Foundation of Hunan Provincial Education Department.
Abstract (Originalsprache)
This study identifies and characterizes ID2-iNeu, a novel antagonist of inhibitor of differentiation-2 (ID2), which exhibits dual bioactivities in promoting neutrophil differentiation and potentiating antitumor efficacy while ameliorating chemotherapy-induced neutropenia. Surface plasmon resonance (SPR) analysis verified the specific binding of ID2-iNeu to human ID2 protein. In vivo experiments in C57BL/6 mice demonstrated that ID2-iNeu markedly elevated neutrophil counts in peripheral blood and spleen, a phenotypic effect not observed for the well-established ID inhibitors AGX51 and AK778-XXMU. In a murine peritonitis model, ID2-iNeu improved bacterial clearance more efficiency, which was closely correlated with the increased abundance of neutrophils. In the B16 melanoma xenograft model, ID2-iNeu exerted potent antitumor activity and synergistically enhanced the therapeutic efficacy of doxorubicin (ADM). Notably, single-agent ADM treatment significantly reduced peripheral neutrophil levels, whereas combinatorial administration with ID2-iNeu effectively reversed ADM-induced neutropenia without exacerbating ADM-associated cardiotoxicity. Bone marrow RNA-sequencing analysis revealed that ID2-iNeu globally remodels the transcriptional profile of hematopoietic differentiation, modulating core signaling pathways (including IGF, PDGF, and Hippo cascades) and key transcription factor families (bHLH, Homeobox, and zf-C2H2), thereby facilitating neutrophil lineage commitment. Molecular docking simulations further revealed that a unique cation-π interaction formed between ID2-iNeu and the Lys58 residue of ID2 protein, which accounts for its distinct functional properties, distinguishing it from the other two ID-targeting compounds AGX51 and AK778-XXMU. Collectively, these findings demonstrate that ID2-iNeu serves as a promising therapeutic candidate for simultaneously alleviating chemotherapy-induced neutropenia and augmenting antitumor therapeutic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological and Chemical Engineering, Changsha University, Changsha 410022, Hunan, China.
- Henan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Henan Medical University, Xinxiang, Henan 453003, China.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
- College of Biological and Chemical Engineering, Changsha University, Changsha 410022, Hunan, China; Changsha Technology Innovation Center for Immune Regulation and Molecular Targeted Drugs, Changsha University, Changsha…
- College of Biological and Chemical Engineering, Changsha University, Changsha 410022, Hunan, China. Electronic address: zhengmiao2021@163.com.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Electronic address: randybinlin@gmail.com.
Förderung
- Hunan Provincial Natural Science Foundation
- Education Department of Hunan Province
- Scientific Research Foundation of Hunan Provincial Education Department
Zitieren
APA
Luo, X., Zheng, S., Liu, B., Gong, X., Zhao, C., Zhang, X., Wu, M., Zheng, M., Lin, B., & Zhong, G. (2026). Targeting ID2 to augment doxorubicin antitumor efficacy and enhance antibacterial defense without neutropenia. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117328
Vancouver
Luo X, Zheng S, Liu B, Gong X, Zhao C, Zhang X, et al. Targeting ID2 to augment doxorubicin antitumor efficacy and enhance antibacterial defense without neutropenia. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117328
BibTeX
@article{Luo2026,
author = {Luo, Xinyu and Zheng, Shuyin and Liu, Biao and Gong, Xue and Zhao, Changhao and Zhang, Xingya and Wu, Minna and Zheng, Miao and Lin, Bin and Zhong, Genshen},
title = {Targeting ID2 to augment doxorubicin antitumor efficacy and enhance antibacterial defense without neutropenia},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.117328}
}
EUVIMED